Before the pandemic started, the Philippines was seen to have steady economic growth, becoming one of the fastest-growing economies in Asia with an average GDP of 6.3 percent over the ten years until 2019.
However, the onset of the global health crisis brought the country’s economy into recession, breaking almost three decades of uninterrupted growth. Since the pandemic started, the country’s COVID-19 cases are now over 1.6 million as per the Department of Health (DOH) data.
Helping alleviate challenges
Aligned with their mission and vision of understanding and meeting the real needs of people, Orient EuroPharma Philippines (OEPP), a company creating innovative, affordable, and high-quality pharmaceutical products for cardiovascular, metabolic, and respiratory infections, initiated a program to help alleviate the challenges in the country.
Through their Project #Hope or Helping Our Patients Every day, OEP recently donated the much-needed Erdosteine to key government COVID-19 medical facilities.
Erdosteine is a mucolytic indicated for the treatment of acute and chronic bronchitis. It has been the subject of numerous clinical trials, showing to be effective as an add-on treatment to Chronic obstructive pulmonary disease (COPD) patients for as long as 12 months.
Adding Erdosteine to the usual treatment therapy of hospitalized patients with COVID-related pneumonia and severe respiratory failure helps improve their overall health-related quality of life, says a study published in Multidisciplinary Respiratory Medicine 2020 journal.